Exclusive: Baidu, investors in talks to raise $2 billion for biotech startup


© Reuters.

By Yingzhi Yang and Brenda Goh

BEIJING/SHANGHAI (Reuters) – Chinese tech giant Baidu (O:) is in talks with investors to raise up to $2 billion over three years for a biotech startup, which will use AI technology to discover new drugs and diagnose diseases, a person with direct knowledge of the matter said.

A second person confirmed the startup plan.

Baidu (O:) is unlikely to be the controlling investor, the first person said. Both sources spoke on condition of anonymity, adding they did not have more details on the investment as talks were still under way.

Baidu’s plans come at a time of increased investment in the healthcare sector since the outbreak of the COVID-19 pandemic, with many companies expanding into online diagnosis options to fill the gaps left by overstretched, overcrowded hospitals.

WeDoctor, backed by Tencent (HK:), Alibaba ‘s (N:) healthcare arm and Ping An Good Doctor (HK:) have joined the fray to develop apps that offer diagnosis, prescriptions, appointment bookings, 1-hour drug delivery and insurance.

But the startup under discussion plans to focus more on such areas as drug discovery and development, and early tumor diagnosis, by mobilizing Baidu’s powerful artificial intelligence (AI) technology that can perform complex computing to produce biological innovations, the sources said.

The name of the startup has not been decided, but Baidu came up with the idea as early as six months ago, one of the sources said, adding that Baidu founder and Chairman Robin Li has been personally involved in the project.

Baidu declined to comment.

Baidu open-sourced its Ribonucleic acid (RNA) prediction algorithm LinearFold this year. The tool aims to accelerate the prediction time of a virus’ RNA secondary structure, which is crucial to understand a virus and develop vaccines.

The healthcare industry, especially biotechnology, has seen a flood of money flow in amid the scramble for a COVID-19 vaccine and governments seeking to fix their health systems.

The Hang Seng Healthcare Index () has surged about 40% over the past five months, outstripping the Hang Seng Index () that edged up more than 6% over the time.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*